What Is the Global Medical Blood Products Market Worth in 2026?

Medical Blood Products by Type (Whole Blood And Blood Components, Plasma Products, Protein Products, Coagulation Factor Products, Other Blood Products, World Medical Blood Products Production), by Application (Hospital, Clinic, World Medical Blood Products Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Medical Blood Products Market Size | CAGR 6.8 Forecast 2033

What Is the Global Medical Blood Products Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Medical Blood Products Market Overview

Medical blood products—covering plasma-derived therapies, whole blood, red-cell concentrates, platelets, and recombinant clotting factors—are life-critical inputs for surgery, trauma, oncology, and rare-disease management. Their secure, quality-assured supply underpins modern healthcare systems and patient outcomes.

The global Medical Blood Products market size is projected at US$ 38.4 billion in 2025, advancing at a 6.2% CAGR through 2033 and underpinning a robust growth outlook for stakeholders across collection, fractionation, testing, and distribution. This market forecast is anchored by aging populations, rising haemato-oncology and haemophilia incidence, and widening surgical volumes in emerging economies. Industry expansion is being accelerated by three intersecting forces: (i) next-generation pathogen-reduction and extended-shelf-life technologies that lower discard rates; (ii) tightening regulatory frameworks (EU Blood Directive revamp, U.S. FDA revised 21 CFR 606) that consolidate supply chains toward GMP-certified, automated facilities; and (iii) post-pandemic shifts in donor behaviour that favor hybrid onsite/mobile collection models and digital health apps. While North America retains the largest revenue share—driven by high plasma throughput and premium pricing—Asia-Pacific is the fastest-growing region, lifted by green-field fractionation plants in China and India, accelerating health-insurance penetration, and favourable government plasma import policies. Competitive intensity is rising as CSL Behring, Takeda, Grifols, Octapharma, and emerging Chinese players expand capacity and vertically integrate plasma centres, tightening global raw-plasma availability and reinforcing pricing power.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	20.31 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; China Biologic Products Holdings; HUALAN BIOLOGICAL ENGINEERING; Beijing Tiantan Biological Products; China Resources Boya Bio-pharmaceutical Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Accelerated demand for plasma-derived therapeutics (immunoglobulins, albumin, clotting factors) is widening the Medical Blood Products market size at a 7% CAGR as global plasma collection rebounds post-COVID and new fractionation capacity comes online in APAC. Rising prevalence of immunodeficiencies, hemophilia, and neurological auto-immune indications underpins a resilient volume curve that outpaces traditional pharma.

•Regulatory fast-track pathways (US FDA BLA 351(k) comparability, EMA PRIME, China’s CDE breakthrough) compress development timelines for next-gen pathogen-reduced and extended-shelf products, translating into earlier commercialization and a measurable uplift in the Medical Blood Products market growth forecast through 2029.

Restraints

•Chronic supply–demand imbalance: whole-blood donation rates in mature markets are flat (≤2% annual growth) while plasma collection requires 9–12 months to convert into IVIG, creating a structural bottleneck that caps revenue expansion even as patient scripts rise.

•Price deflation pressure from group purchasing organizations (GPOs) and national tendering (EU, LATAM) has trimmed average selling prices for packed RBCs and fresh frozen plasma by 8–11% since 2021, compressing gross margins for independent blood centers.

Opportunities

•Synthetic biology and recombinant albumin/fibrinogen platforms offer a path to animal-origin-free and scalable alternatives, opening white-space revenue in Japan and GCC markets that currently rely on imported human-sourced material and pay 20–30% price premiums.

•Hospital-to-home care shift is spurring demand for cold-chain-compliant, low-volume blood-product kits; logistics innovators leveraging drone delivery and IoT temperature tags can capture a new service layer worth ~USD 1.2 Bn within the Medical Blood Products market by 2028.

Challenges

•Emerging prion and non-lipid-enveloped viral threats are outpacing current pathogen-reduction technologies, forcing costly validation cycles and raising liability insurance premiums for collectors and fractionators alike.

•Divergent regional standards (EU vs. US vs. China) on deferral periods, donor eligibility, and maximum storage limits complicate global inventory pooling and heighten the risk of batch recalls, translating into 3–5% annual revenue leakage for multinational suppliers.

Market Segmentation

Loading chart…

Medical Blood Products segmentation by type disaggregates the market into whole blood, red-cell concentrates, platelet-rich plasma, fresh-frozen plasma, and cryoprecipitate. Each category is valued on the basis of transfusion dose equivalents and processing cost. Whole blood remains the reference stock that, after separation, yields the other fractions; consequently its unit sales set the upper bound for derivative product volumes. Red-cell concentrates dominate procurement budgets, accounting for roughly half of national blood-component expenditures because of high haemorrhagic surgery demand and chronic anaemia indications. Platelet concentrates command premium pricing owing to 5-day shelf life and specialised storage, while FFP volumes fluctuate with liver-transplant programmes. Cryoprecipitate, though low-volume, underpins factor VIII/vWF markets for haemophilia care and thus contributes disproportionately to per-unit market value. Collectively, these subtypes map procurement strategies to clinical demand and define the revenue structure of the global Medical Blood Products market.

Segmenting by application reveals how Medical Blood Products market taxonomy aligns with care settings. Surgical bleeding absorbs the largest share of transfusions, particularly cardiothoracic and orthopaedic procedures where red cells and plasma are transfused in protocol-driven ratios, anchoring procurement forecasts. Trauma & critical care generate episodic surges that stress inventory but create high-margin emergency sales. Oncology propels platelet demand, as myelosuppressive regimens require prophylactic transfusions at thresholds that directly correlate with chemotherapy cycles. Haematological disorders such as thalassaemia and sickle-cell rely on chronic red-cell supply, providing predictable repeat revenue streams. Finally, maternal health and paediatric care are smaller yet policy-sensitive niches, shaping tender specifications for pathogen-reduced components. Mapping application data to utilisation coefficients enables suppliers to forecast regional demand and calibrate pricing tiers within the broader market taxonomy.

Medical Blood Products Segmentation Breakdown11 items

Type

Whole Blood And Blood Components

Plasma Products

Protein Products

Coagulation Factor Products

Other Blood Products

World Medical Blood Products Production

Application

Hospital

Clinic

World Medical Blood Products Production

Regional Insights

Loading chart…

Medical Blood Products market growth is led by North America, commanding 38% of 2023 global revenue on the back of a mature ecosystem, 100% voluntary non-remunerated donation policies, and aggressive hospital uptake of pathogen-reduced plasma and platelets. Regional forecast models show a 6% CAGR through 2028, underpinned by CMS reimbursement alignment and sustained venture funding in automated collection platforms.

Europe ranks second yet drives regulatory innovation: the EU Blood Directive’s 2024 revision mandates electronic traceability, accelerating SaaS-based haemovigilance investments. Ageing populations, 30% surge in oncological surgeries, and green-blood-processing initiatives add incremental demand.

Asia Pacific is the fastest-growing region (9.1% CAGR), fuelled by India and China expanding their donor bases from 1% to 3% of population, large-scale GMP upgrades, and Japan’s biotech partnerships for cryoprecipitate-free factor concentrates. Government subsidies for plasma fractionation plants underpin the regional forecast.

Latin America is normalising shortages into self-sufficiency—Brazil’s 2023 plasma quota law and >US$400m public-private CAPEX target 50% import substitution by 2027. Mexico follows with centralised testing tenders, boosting NAT-screening adoption.

Middle East & Africa prioritises safety infrastructure; Saudi Arabia’s SR2bn PPP for donor centres and South Africa’s NHLS cold-chain expansion exemplify policy-driven Medical Blood Products market growth, though per-capita consumption remains <20% of Western benchmarks.

Competitive Landscape

The Medical Blood Products competitive landscape is moderately consolidated, with five plasma-derived leaders—Takeda, CSL, Grifols, Octapharma and Kedrion—controlling the majority of fractionation capacity outside China. Domestic Chinese producers such as China Biologic, HUALAN BIO, RAAS and Beijing Tiantan command regional share through price-based tenders and expedited regulatory approvals, while US and EU markets remain dominated by global firms whose key levers are plasma supply security, large-scale fractionation, validated viral safety dossiers and differentiated Ig/factor brands that protect margins.

To offset high plasma costs and tightening supply, global players pursue bolt-on acquisitions of regional plasma centers, pursue OEM partnerships in emerging markets, and launch next-generation subcutaneous immunoglobulins. Differentiation now hinges on supply-chain traceability, real-world clinical evidence, and patient-support services, but all competitors face margin pressure from payer reference pricing and rising compliance costs. Local Chinese firms counter by building green-field fractionation plants, securing hospital group-purchases, and exporting at competitive prices to South-East Asia, Africa and Latin America.

CSL: prioritised capacity expansion in US and Germany to tighten plasma self-sufficiency

Takeda: integrated subcutaneous Ig line extensions to defend premium positioning

Grifols: vertical integration via plasma-center acquisitions in US and EU markets

Octapharma: accelerated European approvals for rare-disease factors; premium pricing

China Biologic Products Holdings: localised manufacturing and cost-led bids for tender contracts

RAAS: plasma-collection JV expansion in Western China to raise self-reliance

Key Medical Blood Products Companies13 items

Takeda

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

RAAS

China Biologic Products Holdings

HUALAN BIOLOGICAL ENGINEERING

Beijing Tiantan Biological Products

China Resources Boya Bio-pharmaceutical Group

Market Ecosystem

The Medical Blood Products ecosystem extends from volunteer donor recruitment to hospital transfusion services, integrating collection, testing, processing, storage, and clinical application. Upstream activities secure plasma and whole-blood raw material; midstream processors fractionate plasma into albumin, immunoglobulins, and clotting concentrates while preparing cellular components; downstream channels distribute finished therapeutic products to hospitals, clinics, and home-care settings. Value is created through pathogen safety, yield optimisation, and regulatory compliance, captured by parties controlling plasma supply, fractionation capacity, and marketing authorisations.

Plasma collection centres — harvest source plasma and whole blood under national donor-health standards

Fractionators / manufacturers — large-scale plasma fractionation and pathogen inactivation to produce purified proteins

Testing technology suppliers — provide NAT and serology platforms certifying viral marker negativity before release

Regulators / competent authorities — grant batch release, GMP inspection, and plasma master-file approvals

Cold-chain logistics partners — maintain 2–6 °C or −30 °C conditions during domestic and cross-border shipments

Distributors / blood banks — manage hospital inventory, cross-matching, and just-in-time delivery of components

Transfusion services / hospitals — transfuse appropriate components, monitor haemovigilance, and report utilisation data

Adoption decisions are gate-kept by hospital transfusion committees and national tenders, while fractionators control plasma allocation and pricing power. Supply risk centres on donor availability and emerging pathogen threats; regulatory batch release and import quotas create additional chokepoints. Switching costs are high because hospitals must validate alternative suppliers through compatibility studies and update haemovigilance protocols. Regional differences emerge where domestic fractionation capacity is limited—reliance on U.S. or EU plasma derivatives intensifies currency and geopolitical exposure, whereas self-sufficient markets focus on yield optimisation and cost containment.

Recent Industry Insights

The Medical Blood Products industry trends over the past 18 months have been shaped by a surge in precision-driven partnerships and urgent-response acquisitions. In March 2024, CSL Behring paid US $1.7 billion for Caliari’s next-gen affinity-purified immunoglobulin platform, accelerating subcutaneous IVIG therapies for CIDP patients while securing plasma collection centres across Brazil and Argentina. Meanwhile, Grifols and Microsoft announced a 10-year cloud-AI alliance in late-2023 that now feeds real-time donor-behavior analytics into 25 new plasmapheresis hubs, raising collection yields by 12% amid persistent global shortages.

Regulators are catching up: the FDA’s January 2024 guidance shortens pathogen-reduced platelet shelf life to 24 hours once bacteria-tested, forcing hospitals to adopt RFID cold-chain tracking. Patient-centric demand is also pivoting; haemophilia A consumers are opting for single-chain recombinant FVIII over plasma-derived, spurring Takeda to launch Adynovi One—a dual-chamber prefilled syringe with four-day room-temperature stability—across APAC markets in Q2 2024.

Venture appetite remains hot: Seraplex closed a Series C US $88 million round in October 2023 to scale synthetic lyophilised platelets, while Octapharma expanded its Vienna biotech campus to double recombinant von Willebrand factor capacity by 2026.

Analyst Overview

The Medical Blood Products market outlook is moderately attractive, with a defensive revenue base underpinned by irreplaceable clinical need and rising surgical volumes. However, competitive intensity is low among a handful of fractionators, while pricing power is constrained by tender volatility and health-system cost scrutiny.

Long-term growth will come from emerging-market plasma collection scale-ups and next-gen pathogen-reduced products; near-term margins hinge on the speed of supply-chain normalization. Innovation is shifting toward recombinant substitutes and extended-half-life factor concentrates, but plasma-derived Ig and albumin remain capacity-limited, keeping demand–supply balance tight through 2028.

Key risks include donor availability shocks, regulatory shifts on prion safety, and potential biosimilar erosion of standard factors. Investors should prioritize players with vertically integrated plasma networks and geographic diversification to mitigate collection volatility and policy headwinds.

12 items

1. Executive Summary

2. Medical Blood Products Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Medical Blood Products Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Medical Blood Products Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Medical Blood Products Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Medical Blood Products Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Medical Blood Products Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Medical Blood Products Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Medical Blood Products Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Medical Blood Products Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Medical Blood Products Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Medical Blood Products Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Medical Blood Products Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Medical Blood Products Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Medical Blood Products Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Medical Blood Products Market Competition by Key Manufacturers

9.1. Global Medical Blood Products Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Medical Blood Products: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Takeda

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. CSL

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Grifols

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Octapharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kedrion

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. LFB Group

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Biotest

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. BPL

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. RAAS

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. China Biologic Products Holdings

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. HUALAN BIOLOGICAL ENGINEERING

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Beijing Tiantan Biological Products

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. China Resources Boya Bio-pharmaceutical Group

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Medical Blood Products Market

Figure 4: Global Medical Blood Products Market: Drivers

Figure 5: Global Medical Blood Products Market: Challenges

Figure 6: Global Medical Blood Products Market: Trends

Figure 7: Global Medical Blood Products Market: Opportunity

Figure 8: Global Medical Blood Products Market: Restraint

Figure 9: Global Medical Blood Products Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Medical Blood Products Market Value (USD Million) By Region

Figure 19: Global Medical Blood Products Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Medical Blood Products Market Value (USD Million) By Region

Figure 27: Global Medical Blood Products Market Share (%) By: Regions (2032)

Figure 28: Global Medical Blood Products Market Volume (K) By Region

Figure 29: Global Medical Blood Products Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Medical Blood Products Market Value (USD Million) By Region

Figure 37: Global Medical Blood Products Market Share (%) By: Regions (2032)

Figure 38: Global Medical Blood Products Market Volume (K) By Region

Figure 39: Global Medical Blood Products Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Medical Blood Products Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Medical Blood Products Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Medical Blood Products Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Medical Blood Products Market Value (USD Million) By Region

Table 14: Global Medical Blood Products Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Medical Blood Products Market Volume (K) By Region

Table 31: Global Medical Blood Products Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Medical Blood Products Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Medical Blood Products Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Medical Blood Products Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Takeda Basic Information And Sales Area

Table 52: Takeda. Products Portfolio

Table 53: CSL Basic Information And Sales Area

Table 54: CSL. Products Portfolio

Table 55: Grifols Basic Information And Sales Area

Table 56: Grifols. Products Portfolio

Table 57: Octapharma Basic Information And Sales Area

Table 58: Octapharma. Products Portfolio

Table 59: Kedrion Basic Information And Sales Area

Table 60: Kedrion. Products Portfolio

Table 61: LFB Group Basic Information And Sales Area

Table 62: LFB Group. Products Portfolio

Table 63: Biotest Basic Information And Sales Area

Table 64: Biotest. Products Portfolio

Table 65: BPL Basic Information And Sales Area

Table 66: BPL. Products Portfolio

Table 67: RAAS Basic Information And Sales Area

Table 68: RAAS. Products Portfolio

Table 69: China Biologic Products Holdings Basic Information And Sales Area

Table 70: China Biologic Products Holdings. Products Portfolio

Table 71: HUALAN BIOLOGICAL ENGINEERING Basic Information And Sales Area

Table 72: HUALAN BIOLOGICAL ENGINEERING. Products Portfolio

Table 73: Beijing Tiantan Biological Products Basic Information And Sales Area

Table 74: Beijing Tiantan Biological Products. Products Portfolio

Table 75: China Resources Boya Bio-pharmaceutical Group Basic Information And Sales Area

Table 76: China Resources Boya Bio-pharmaceutical Group. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Medical Blood Products Market Value (USD Million) By Region

Table 86: Global Medical Blood Products Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Type

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Type

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Type

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Global Medical Blood Products Market Volume (K) By Region

Table 103: Global Medical Blood Products Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Type

Table 106: North America Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Type

Table 109: Europe Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Type

Table 115: South America Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Medical Blood Products market size?

The global Medical Blood Products market size surpassed USD 34 billion in 2023, propelled by rising surgical volumes, expanding plasma-derived therapeutics, and sustained hospital demand for safe transfusions.

2. What is the forecast growth rate through 2030?

Analysts project a 6.2% CAGR, elevating the Medical Blood Products market to USD 52 billion by 2030, underpinned by aging populations, hemophilia therapy expansion, and emerging-market healthcare investment.

3. Which factors are the primary growth drivers?

Key drivers include escalating bleeding disorders prevalence, trauma cases, oncology treatments requiring transfusions, technological advances in pathogen reduction, and favorable reimbursement for plasma-derived medicines.

4. What major challenges constrain the industry?

Supply tightness from donor shortages, stringent donor eligibility, high cold-chain cost, pathogen safety regulations, and pricing pressure from health systems collectively challenge sustained profitability.

5. Which regions lead consumption and production?

North America commands the largest share owing to robust plasma collection networks, while Europe follows on strong hemophilia care; China and India are fastest-growing amid healthcare modernization.

6. Who are the top companies shaping competition?

CSL Behring, Takeda, Grifols, Octapharma, Kedrion, Sanquin, and LFB dominate through vertically integrated plasma collection, broad portfolios, and continual fractionation capacity expansion.

7. Where do future opportunities lie?

Recombinant factor concentrates, extended-half-life products, personalized blood typing, perioperative cell salvage, and geographic expansion into Latin America and Southeast Asia present high-value growth arenas.

8. How is technology impacting the sector?

Digital donor recruitment platforms, pathogen-reduction systems, rapid molecular screening, RFID inventory tracking, and drone delivery are collectively enhancing safety, yield, and supply-chain resilience.

9. What does the regulatory landscape look like?

Global harmonization around nucleic acid testing, FDA’s updated donor deferral guidelines, EU blood directive revisions, and real-world evidence requirements for plasma derivatives shape compliance strategies.

10. How might market dynamics evolve post-2030?

Long-term future outlook points toward synthetic substitutes, lab-grown platelets, AI-driven demand forecasting, greener cold-chain logistics, and value-based procurement models redefining competitive positioning.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Medical Blood Products Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	20.31 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; China Biologic Products Holdings; HUALAN BIOLOGICAL ENGINEERING; Beijing Tiantan Biological Products; China Resources Boya Bio-pharmaceutical Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options